ERBB2 and neoplasm: As suggested by Tarantino et al., successful targeting of HER2 in nonamplified tumors has the potential to alter the current treatment landscape in several ways, including mitigation of oncogene dependency (as novel ADCs may exert their antitumor activity regardless of tumor cell dependency on the HER2 pathway), higher DAR/alternative payload mechanisms of action, and the use of modern cleavable linkers that have the potential to facilitate the “bystander effect”.